Augmented Renal Vancomycin Clearance in Cancer Patients: A Case Report and Review of the Literature

被引:11
作者
Curth, Harald-Morten [1 ]
Pelc, Agnes [1 ]
Kuetting, Fabian [1 ]
Steffen, Hans-Michael [1 ]
机构
[1] Univ Hosp Cologne, Dept Gastroenterol & Hepatol, D-50937 Cologne, Germany
关键词
Palliative care; Inflammation; Pharmacokinetics; Dose-response relationship; drug; HEMATOLOGICAL MALIGNANCIES; PHARMACOKINETICS;
D O I
10.1159/000377652
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Bacterial infections are a major cause of morbidity and mortality in cancer patients. Particularly diagnostic and therapeutic procedures (e.g. central venous catheters, paracentesis) increase the risk of infections in this immunocompromised patient population. In the past, antibiotic therapy was empirically initiated in these patients, guided by treatment regimens designed for patients without malignancy; however, the hyperdynamic circulation in systemic inflammatory response syndrome, as well as the presence of malignancy itself, may have a crucial impact on treatment success. Case Report: Here, we report the case of a 55-year-old patient with advanced pancreatic cancer and Staphylococcus epidermidis bacteremia who, due to increased renal vancomycin clearance, required treatment with high doses of vancomycin in order to reach therapeutic trough levels. Conclusion: Oncological status can be a cofactor of altered pharmacokinetics in terms of a paraneoplastic syndrome. With the help of this case report we want to call attention to this clinically significant phenomenon with its inherent risk of inefficient antibiotic treatment.
引用
收藏
页码:182 / 184
页数:3
相关论文
共 9 条
[1]   Tumour necrosis factor and cancer [J].
Balkwill, Frances .
NATURE REVIEWS CANCER, 2009, 9 (05) :361-371
[2]   Augmented renal clearance in septic patients and implications for vancomycin optimisation [J].
Baptista, Joao Pedro ;
Sousa, Eduardo ;
Martins, Paulo J. ;
Pimentel, Jorge M. .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2012, 39 (05) :420-423
[3]   Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies [J].
Buelga, DS ;
de Gatta, MDF ;
Herrera, EV ;
Dominguez-Gil, A ;
García, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (12) :4934-4941
[4]   INFLUENCE OF MALIGNANCY ON THE PHARMACOKINETICS OF VANCOMYCIN IN INFANTS AND CHILDREN [J].
CHANG, D .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1995, 14 (08) :667-673
[5]   A Retrospective Analysis of Vancomycin Pharmacokinetics in Japanese Cancer and Non-cancer Patients Based on Routine Trough Monitoring Data [J].
Omote, Shinobu ;
Yano, Yoshitaka ;
Hashida, Tohru ;
Masuda, Satohiro ;
Yano, Ikuko ;
Katsura, Toshiya ;
Inui, Ken-ichi .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2009, 32 (01) :99-104
[6]   Correlation of Pharmacokinetic Parameters with Serum Vancomycin Concentration in Elderly Patients with Malignancies [J].
Sadoh, Shinichi ;
Tsuji, Yasuhiro ;
Tsukamoto, Kazuhiro .
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2010, 130 (01) :69-73
[7]  
Shimada I, 2012, ANTICANCER RES, V32, P823
[8]   Systemic inflammatory response syndrome criteria and vancomycin dose requirement in patients with sepsis [J].
Shimamoto, Yuko ;
Fukuda, Tsuyoshi ;
Tanaka, Kazuhiko ;
Komori, Katsuya ;
Sadamitsu, Daikai .
INTENSIVE CARE MEDICINE, 2013, 39 (07) :1247-1252
[9]   Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States [J].
Wisplinghoff, H ;
Seifert, H ;
Wenzel, RP ;
Edmond, MB .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (09) :1103-1110